300683 Wuhan Hiteck Biological Pharma
- 20.13
- -0.58-2.80%
Wuhan Hiteck Biological Pharma News
Haite Biotech: SDIC Securities Co., Ltd.\'s 2024 semi-annual regular on-site inspection report on the company\'s continuous supervision work
Haite Biotech: SDIC Securities Co., Ltd.\'s 2024 semi-annual continuous supervision and follow-up report
Haite Biotech: Announcement on obtaining a registration certificate for injectable esomeprazole sodium drugs
Haite Biotech: SDIC Securities Co., Ltd.\'s inspection opinion on the extension of some of the company\'s fund-raising investment projects
Haite Biotech: Announcement of Supervisory Board Resolutions
Haite Biotech: Announcement of Board Resolutions
Haite Biotech: Special Report on the Deposit and Use of Funds Raised for the Semi-Annual Year 2024
Wuhan Hiteck Biological Pharma: Announcement of Resolutions of the Sixteenth Meeting of the Eighth Board of Directors.
Wuhan Hiteck Biological Pharma: Announcement of the Resolution of the Sixteenth Meeting of the Eighth Supervisory Board.
Wuhan Hiteck Biological Pharma: Notice on obtaining a drug registration certificate for injectable roxatidine hydrochloride acetate
Wuhan Hiteck Biological Pharma: 300683 Haite Biotech Investor Relations Management Information 20240531
Wuhan Hiteck Biological Pharma: Announcement on participating in the 2024 Online Group Reception Day for Investors of Listed Companies under the jurisdiction of Hubei
Wuhan Hiteck Biological Pharma: Announcement on receiving government subsidies
Wuhan Hiteck Biological Pharma: China Investment Securities Co., Ltd. inspection opinions on the company's 2023 internal control self-evaluation report
Wuhan Hiteck Biological Pharma: Special inspection opinions of SDIC Securities Co., Ltd. on the storage and use of funds raised by the company in 2023
Wuhan Hiteck Biological Pharma: China Investment Securities Co., Ltd.'s regular on-site inspection report on the company's continuous supervision work for the second half of 2023
Wuhan Hiteck Biological Pharma: SDIC Securities Co., Ltd.'s 2023 Continuous Supervision and Follow-up Report on the Company
Wuhan Hiteck Biological Pharma: 300683 Haite Biotech Investor Relations Management Information 20240429
Wuhan Hiteck Biological Pharma: 300683 Haite Biotech Investor Relations Management Information 20240429
Hyte Biotech: Announcement of Supervisory Board Resolutions
Analysis
Price Target
No Data
No Data